Roger Tell

Chief Tech/Sci/R&D Officer at ISOFOL MEDICAL AB

59 year

Health Technology

Consumer Services

Profile

Roger Tell is currently the Director at Vivesto AB since 2022 and the Chief Scientific & Medical Officer at Isofol Medical AB since 2019.
Previously, he worked as the Vice President-Clinical Development at Aprea Therapeutics AB.
Dr. Tell obtained his doctorate degree from Karolinska Institutet in 1998.

Roger Tell active positions

Companies	Position	Start
ISOFOL MEDICAL AB	Chief Tech/Sci/R&D Officer	2019-01-31
VIVESTO AB	Director/Board Member	2022-05-24

All active positions of Roger Tell

Former positions of Roger Tell

Companies	Position	End
Aprea Therapeutics AB Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden.	Corporate Officer/Principal	2019-01-31

See the detail of Roger Tell's experience

Training of Roger Tell

Karolinska Institutet

Doctorate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Roger Tell's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	2
VIVESTO AB	Health Technology
ISOFOL MEDICAL AB	Health Technology

Private companies	1
Aprea Therapeutics AB Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden.	Health Technology